Risk factors for tardive movement disorders in schizophrenia;Risicofactoren van tardieve bewegingsstoornissen bij schizofrenie

Tijdschrift voor Psychiatrie

Volumn 57, Issue 2, 2015, Pages 120-124

  Tenback, D E ^a   Bakker, P R ^b   Van Harten, P N ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acathisia; Dyskinesia; Epidemiology; Movement disorders; Risk factors; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CAUCASIAN; DISEASE CLASSIFICATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDLINE; MOTOR DYSFUNCTION; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TARDIVE MOVEMENT DISORDER; AGE; ANCESTRY GROUP; META ANALYSIS; MOVEMENT DISORDERS;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; CONTINENTAL POPULATION GROUPS; HUMANS; MOVEMENT DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84924356387     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN. Candidate gene- based association study of antipsychotic- induced movement disorders in long-stay psychiatric patients: A prospective study. PLoS One 2012; 7:636561.
2. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYPiA2and MnSODgenes:A meta analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13:544-56.
3. Barnes TR, Gervin M. Assessment of drug-related movement disorders in schizophrenia. Adv Psychiatr Treat 2000; 6:331-42.
4. Burke RE, Kang UJ.Tardive dystonia: clinical aspects and treatment. Adv Neurol 1988; 49:199-210.
5. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53:313-9.
6. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(4 Suppl):2S-6S.
7. Correll, CU and Schenk, EM (2008).Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21:151-6.
8. Emsley R, Turner HJ, Oosthuizen PP, Carr J. Neurological abnormalities in first- episode schizophrenia: Temporal stability and clinical and outcome correlates. Schizophr Res 2005; 75:35-44.
9. Hansen LK, Nausheen B, Hart D, Kingdon D. Movement disorders in patients with schizophrenia and a history of substance abuse. Hum Psychopharmacol 2013; 28: 192-7.
10. Harten PN van, Hoek HW, Matroos GE, Koeter M, Kahn RS.The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: The Curacao Extrapyramidal Syndromes Study II. Schizophr Research 1997; 26:235-42.
11. Harten PN van, Hoek HW, Matroos GE, van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: The Curacao extrapyramidal syndromes study V.J Clin Psychiatry 2006; 67:1920-7.
12. Harten PN van, Tenback DE. Movement disorders should be a criterion for schizophrenia in DSM-V. Psychol Medicine 2009;39:1754-6.
13. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. (2002). Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene SergGly polymorphism. Neuropsychopharmacol 2002;27:105-19.
14. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, et al. Combined analysis of 635 patients confirms an age- related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005 18: 411-25.
15. Mittal VA, Jalbrzikowski M, Daley M, Roman C, Bearden CE, Cannon TD. Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis. Schizophr Res 2011; 130:164-9.
16. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64: 1075-80.
17. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic- naive patients with first-episode psychoses: A systematic review. Psychol Med 2009;39:1065-76.
18. Patsopoulos NA, Ntzani EE, Zintzaras E, loannidis JP.CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenias meta-analysis. Pharmacogenet Genomics 2005; 15:151-8.
19. Straus RD, Alvir JM, Robinson D, Gal G, Sheitman B, Chakos M, et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull 2004; 30:265-78.
20. Tenback DE, van Harten PN, SIooff CJ, van Os, J (2006). Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacol 2006; 31:1832-7.
21. Tenback DE, van Harten PN, SIooffCJ, van Os J. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry 2007; 48:436-40.
22. Tenback DE, van Harten PN, van Os J. Non- Therapeutic risk factors for onset of tardive dyskinesia in schizophrenias meta analysis. Mov Disord 2009; 24:2309-15.
23. Thelma B, Srivastava V., Tiwari AK.Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9:1285-306.
24. Tsai HT, North KE, West SL, Poole C. The DRD3 rs628o polymorphism and prevalence of tardive dyskinesia: A meta analysis. Am J Med Gen B Neuropsychiatr Genet 2010; 153B: 57-66.
25. Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, et al. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. Schizophr Res 2014; 153: 184-8.
26. Zai CC., Tiwari AK, Basile V, de Luca, V, Muller DJ, Voineskos AN, et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NOOi) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:50-6.
27. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: A metaanalysis. Am J Psychiatry 2010; 167:763-72.